Monte Rosa Therapeutics reports positive MRT-8102 Phase 1 results
GLUE•Monte Rosa Therapeutics said its MRT-8102 Phase 1 GFORCE-1 study showed normalization of key pathogenic drivers of ASCVD in subjects with elevated cardiovascular risk. The company plans to initiate multiple Phase 2 studies in high-unmet-need indications.
1. Study results
Monte Rosa Therapeutics announced positive results from its GFORCE-1 Phase 1 study of MRT-8102, showing normalization of key pathogenic drivers of ASCVD in subjects with elevated cardiovascular risk. The company plans to initiate multiple Phase 2 studies of MRT-8102 in high-unmet-need indications.
